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Cancer stem cells (CSCs) are rare cancer cells that are postulated to be responsible for cancer relapse and metastasis.
However, CSCs are difficult to isolate and poorly understood. Here, a bioinspired approach for label-free isolation and
culture of CSCs, by microencapsulating one cancer cell in the nanoliter-scale hydrogel core of each prehatching embryo-
like core–shell microcapsule, is reported. Only a small percentage of the individually microencapsulated cancer cells can
proliferate into a cell colony. Gene and protein expression analyses indicate high stemness of the cells in the colonies.
Importantly, the colony cells are capable of cross-tissue multilineage (e.g., endothelial, cardiac, neural, and osteogenic)
differentiation, which is not observed for “CSCs” isolated using other contemporary approaches. Further studies demon-
strate the colony cells are highly tumorigenic, metastatic, and drug resistant. These data show the colony cells obtained
with the bioinspired one-cell-culture approach are truly CSCs. Significantly, multiple pathways are identified to upregulate
in the CSCs and enrichment of genes related to the pathways is correlated with significantly decreased survival of breast
cancer patients. Collectively, this study may provide a valuable method for isolating and culturing CSCs, to facilitate the
understanding of cancer biology and etiology and the development of effective CSC-targeted cancer therapies.
Prof. H. Wang, Dr. B. Jiang, S. Stewart, Y. Liang, Prof. J. P. Fisher,
Prof. X. He
Fischell Department of Bioengineering
University of Maryland
College Park, MD 20742, USA
E-mail: wanghai@nanoctr.cn; shawnhe@umd.edu
Prof. H. Wang
CAS Key Laboratory for Biomedical Effects of Nanomaterials &
Nanosafety
CAS Center for Excellence in Nanoscience
National Center for Nanoscience and Technology
Beijing 100190 China
Prof. H. Wang
University of Chinese Academy of Sciences
Beijing 100049 China
Prof. H. Wang, Dr. P. Agarwal, Prof. X. He
Department of Biomedical Engineering
The Ohio State University
Columbus OH 43210, USA
The ORCID identification number(s) for the author(s) of this article
can be found under https://doi.org/10.1002/advs.202000259
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim. This is an open access article under the terms of the
Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly
cited.
DOI: 10.1002/advs.202000259
X. Liu, Prof. Z. Liu
Division of Cardiovascular Medicine
Center for Precision Medicine
University of Missouri School of Medicine
Columbia MO 65212, USA
Dr. B. Hancioglu, Dr. A. Webb
Department of Biomedical Informatics
The Ohio State University
Columbus OH 43210, USA
Prof. X. Lu
Department of Medical and Molecular Genetics and Melvin and Bren
Simon Cancer Center
Indiana University School of Medicine
Indianapolis IN 46202, USA
Prof. K. H. R. Tkaczuk, Prof. X. He
Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Maryland
Baltimore MD 21201, USA
Prof. X. He
Robert E. Fischell, Institute for Biomedical Devices
University of Maryland
College Park MD 20742, USA
Adv. Sci. 2020, 7, 2000259 2000259 (1 of 12) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advancedscience.com
1. Introduction
There is mounting evidence that suggests a small subset of can-
cer cells possesses the exclusive capability of forming tumors,
and these cells are often called cancer stem cells (CSCs) or tumor
initiating cells.[1] CSCs have been posited to be responsible for
the failure of thewidely used chemo- and radiotherapies of cancer
due to their drug resistance and high capability of tumorigenesis
andmetastasis, and cancer treatments could bemademore effec-
tive by targeting and killing the CSCs.[2] Unfortunately, the CSCs
are elusive, and their biology is poorly understood up to date.
Therefore, establishing a reliable approach to isolate and culture
CSCs is invaluable for not only improving our understanding of
the CSCs but also developing effective therapeutic strategies for
cancer therapy via targeting the CSCs.
“CSCs” have been isolated based on surface markers, such as
CD44, CD133, CD24, epithelial cell adhesionmolecule (EpCAM),
aldehyde dehydrogenase 1 (ALDH1), and adenosine triphosphate
(ATP)-binding cassette B5 (ABCB5).[3] This isolation method
often causes confusion. This is because two or more surface
makers have been used to identify CSCs from the same type of
cancer in different studies, but co-expression of the different sur-
face markers among the selected CSCs is limited.[4] For example,
either ALDH1+ or CD44+CD24−/low has been used to select CSCs
of breast cancer, but a surprisingly small percentage (0.1–1.2%) of
the CSCs expresses both markers simultaneously.[5] For pancre-
atic cancer, either CD44+CD24+ESA(epithelial-specific antigen)+
or CD133 has been used to select its CSCs, while only 10–40% of
the CD44+CD24+ESA+ cells in primary tumors are shown to be
positive for CD133 expression.[6] Similarly, the EpCAM+CD44+
colorectal CSCs exhibit little overlap with the CD133+
population.[7] In essence, it appears that none of these markers
are consistently expressed on the solid tumor CSCs and the spe-
cific CSC marker(s) for a given type of cancer is still unknown.
Another widely used method for obtaining “CSCs” is to enrich
them with suspension culture in defined CSC medium without
serum.[8] Although hanging drops,[9] gyratory rotation and spin-
ner flask,[10] and NASA rotary cell culture systems[11] have been
developed to enrich CSCs via suspension culture, ultralow attach-
ment plates (ULAPs) are most commonly used to enrich CSCs
in suspension for various types of cancers.[12] The hypothesis is
that only CSCs could survive and form cell aggregates/spheroids,
while non-CSCs should die of anoikis during the suspension
culture. To investigate CSC isolation by this method, four hu-
man cancer cell lines (MDA-MB-231, PC-3, MCF-7, and OVCAR-
8 cancer cells) were cultured with the ULAP method to evaluate
their capability of forming spheroids. As shown in Figure S1a–d
(Supporting Information), the MDA-MB-231 triple negative hu-
man breast cancer cells and PC-3 human prostate cancer cells
can form some loose aggregates, while the MCF-7 human epi-
dermal growth factor (EGF) receptor 2 (HER2)+ human breast
cancer cells and OVCAR-8 human ovarian cancer cells can form
tight cell spheroids under the ULAP culture. We do not call the
aggregates of MDA-MB-231 and PC-3 cells as spheroids because
the aggregates can be easily detached/dissociated into single cells
by gentle pipetting for 5 times. Furthermore, we cultured the four
types of cancer cells at 1–20,000 cells per well in the ULAP. Sur-
prisingly, we noticed that more than 90% of the cells could sur-
vive and grow into aggregates or spheroids under the suspen-
sion culture. This suggests that the suspension culture method
for CSC isolation based on the anoikis of non-stem cancer cells is
questionable as CSCs are considered to be rare in the cancer cell
population. Taken together, the CSCs remain elusive today and
it is challenging and confusing to isolate and/or culture them
with the contemporary approaches based on surface marker(s)
and/or simple suspension culture. Therefore, the development
of a marker-free method for effective isolation and culture of true
CSCs is in need.
2. Results and Discussion
2.1. Bioinspired one cell culture for isolating CSCs
To address the aforementioned challenges and efficiently isolate
and culture CSCs, we have been inspired by the nature’s ap-
proach of culturing stem cells in the prehatching embryos, which
starts from one cell (zygote) that proliferates into a cell colony
(morula) in a miniaturized (nanoliter) core surrounded by a shell
known as the zona pellucida.[13] More specifically, we fabricated
miniaturized, three-dimensional (3D), prehatching embryo-like,
core–shell microcapsules to encapsulate one single cancer cell in
the nanoliter-scale hydrogel core of each of the microcapsules for
CSC isolation and culture. Thismimics the formation of stem cell
colony (i.e., morula) from one cell (i.e., zygote) in the prehatch-
ing embryo. To achieve this, a microfluidic device was used to
fabricate the one cancer cell-laden core–shell hydrogel microcap-
sules with a core diameter of 206.5± 19.7 µm and shell thickness
of 40.5 ± 14.2 µm (Figure 1a and Figure S2, Supporting Infor-
mation). Since recent studies show that the 3D hydrogel/scaffold
may induce anoikis of non-stem cancer cells,[14] we applied an
alginate-based hydrogel scaffold in the core of themicrocapsules.
Alginate is used because it is highly biocompatible and does not
have cell adhesion molecules.[15] The latter is good for inducing
anoikis of non-stem cancer cells. To optimize the concentration
of alginate, the aforementionedMDA-MB-231,MCF-7, PC-3, and
OVCAR-8 cancer cells were cultured in alginate hydrogel scaf-
folds with concentrations ranging over 0.5–3 wt%. As shown in
Figure S3a–d (Supporting Information), few cancer cells can pro-
liferate or survive in the 2% and 3% alginate hydrogels. There-
fore, 2% alginate was utilized as the core scaffold of themicrocap-
sules to induce anoikis of non-stem cancer cells. Furthermore,
hyaluronan (HA, 0.5 wt%) was embedded in the core as it could
play a key role in the CSC niche.[16] The shell of the microcap-
sules was fabricated with pure alginate hydrogel (2%, Figure 1a).
A stable core–shell structure was observed in the resultant mi-
crocapsules with an overall size of ∼300 µm (Figure S4a, Sup-
porting Information). However, the HA (labeled with fluorescein
isothiocyanate or FITC in short) may gradually diffuse out of
the microcapsules during 5 days of incubation in medium. To
overcome this, we further incubate the microcapsules sequen-
tially with chitosan and alginate (Figure 1b), to form an alginate-
chitosan-alginate (ACA) coating (Figure S4b, Supporting Infor-
mation, where the alginate in the ACA coating is labeled with
FITC) on the microcapsule surface for reducing the shell perme-
ability. This effectively prevents the leaking of HA from the mi-
crocapsule core (Figure S4c, Supporting Information) although
the coatings are very thin and do not significantly change the
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Figure 1. The bioinspired one single cell microencapsulation for isolation and culture of cancer stem cells (CSCs). a) A schematic illustration of the one
single cell microencapsulation using a nonplanar microfluidic system. Alginate (A) and hyaluronan (HA or H) are used to form the AH core scaffold
while the shell is formed with alginate hydrogel. The one single cell is located in the core of the core–shell microcapsule. b) To keep the HA (H) inside
the core–shell microcapsules, the outer surface of the alginate (A) shell is coated with chitosan (C) first and then alginate (A) through electrostatic
interactions to form an ACA coating on the surface, resulting in the ACA@AH core–shell microcapsules. c) A schematic illustration of the one single
cell microencapsulation for isolating and culturing CSCs in defined CSC medium: only the CSCs could survive and proliferate in the 3D AH core scaffold
of the miniaturized core–shell microcapsules, while the non-stem cancer cell should die of anoikis. d) Histogram showing the distribution of empty
microcapsules and microcapsules with 1–4 cells after microfluidic encapsulation. We have not seen microcapsules with more than 4 cells under the
condition used in this study. e) Typical micrographs showing the morphology and growth of one (1) single MDA-MB-231 triple negative human breast
cancer cell in the ACA-coated (by default) core–shell microcapsule with HA (H) in the core (ACA@AH-1 or 1csc), multipleMDA-MB-231 cells (10–15 cells
per microcapsule) in the ACA-coated core–shell microcapsules with HA in the core (Mcells), MDA-MB-231 cells under conventional suspension culture
in ultralow attachment plate (Ucells), and MDA-MB-231 cells under 2D culture (2Dcells). f) Approximately 4.4% of the MDA-MB-231 cells could form
colonies (note: a cell colony refers specifically to a cell spheroid grown from one cell in this study) under the 1csc (ACA@AH-1) culture. Almost no one
single MDA-MB-231 cell could survive in either the core–shell microcapsules without ACA coating but with HA in the core (A@AH-1) or the ACA-coated
core–shell microcapsules without HA in the core (ACA@A-1). However, cell spheroid could be seen inmost of the ACA@AHmicrocapsules encapsulated
with multiple (M) MDA-MB-231 cells (Mcells) after 7 days of culture. MDA-MB-231 cells under the Ucells culture could form loose aggregates in 7 days
while the cells under the 2Dcells culture could attach on the 2D substrate and proliferate to ∼80–90% confluency in 3 days. g) Serial passaging assay
showing more than 50% of the cells in the 1csc colonies could form new generations of colonies under the 1csc culture. The first-passage 1csc (1csc-
P1) culture is the same as the 1csc group in (e, f), while 1csc-P2 and 1csc-P3 represent the second- and third-passage 1csc culture using single cells
dissociated from the 1csc-P1 and 1csc-P2 colonies, respectively.
overall size of the microcapsules. By combining the bioinspired
one single cell culture and miniaturized 3D hydrogel scaffold
selection (Figure 1c), we hypothesized that only the one single
CSC in the ACA-coated microcapsules consisting of a core scaf-
fold of both alginate and HA and an ACA-coated alginate shell
(ACA@AH: A for alginate, H for HA, and C for chitosan) could
survive and proliferate during culture.
To test the hypothesis, we quantified the efficiency of ob-
taining one single cell in the microcapsules after microfluidic
encapsulation first. As shown in Figure 1d and Figure S5 (Sup-
porting Information), ∼20% of the ACA@AH microcapsules
contained one single cell, whereas∼4%of themicrocapsules con-
tained two or more cells (which were removed from the samples
immediately by pipetting). Furthermore, viability of the one sin-
gle MDA-MB-231 cell in the ACA@AH microcapsule is greater
than 90% (Figure S6a, Supporting Information) and the cell
could attach and proliferate on the regular cell culture plate af-
ter releasing them out of the microcapsules by dissolving the al-
ginate hydrogel in the microcapsules with an isotonic solution
of sodium citrate and pipetting (Figure S6b, Supporting Infor-
mation). The one single cell cultured in each of the ACA@AH
microcapsule in CSC medium (1csc culture) could form a cell
colony (note: we use the term colony only for spheroid grown
from one cell) in 21 days (Figure 1e). The cell proliferates slowly
during the first and the last 7 days, but fast during days 7–14 (Fig-
ure S6c, Supporting Information). Unlike the MDA-MB-231 cell
aggregates obtained from the conventional ULAP culture (Ucells,
Figure 1e) that easily dissociate into single cells after pipetting for
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5 times (Figure S1a, Supporting Information), colonies obtained
from the 1csc culture are stable even after dissolving the mi-
crocapsules with sodium citrate and pipetting for 10 times (Fig-
ure S6d, Supporting Information). Importantly, only ∼4.4% of
the MDA-MB-231 cells under the 1csc culture could survive and
proliferate to form a colony (Figure 1f). However, essentially no
colonies could be observed either in the absence of the ACA coat-
ing (A@AH-1) to keep HA inside the microcapsules or without
HA in the core alginate hydrogel scaffold (ACA@A-1), confirm-
ing that HA plays a pivotal role in the survival and proliferation of
CSCs (Figure 1f). However, when encapsulating multiple MDA-
MB-231 cells in the ACA@AH microcapsules (∼10–15 cells per
microcapsules, Mcells in short, Figure 1e), cell spheroids are ob-
served in more than 67% of the microcapsules after only 7 days
of culture (Figure 1f). This suggests that the bioinspired use of
one single cell is crucial for CSC isolation.
The self-renewal/stemness of the survived cells is then stud-
ied with the serial passaging assay first, for which detached cells
obtained by dissociating the first-passage 1csc (1csc-P1 or 1csc
by default) colonies were encapsulated in the ACA@AH micro-
capsules (one cell in each microcapsule) for culture to form the
second-passage (1csc-P2) colonies. Strikingly, more than 50% of
the encapsulated one single cell can survive and proliferate to
form colonies (Figure 1g and Figure S7, Supporting Informa-
tion). Similar results are obtained when single cells dissociated
from the 1csc-P2 colonies are encapsulated in the ACA@AHmi-
crocapsules (one cell in each microcapsule) for culturing to form
the third-passage (1csc-P3) colonies (Figure 1g and Figure S7,
Supporting Information). These serial passaging data suggest
that the cells isolated with the one single cell culturemethod (i.e.,
1csc culture) are likely CSCs. The capability of isolating CSCs
with the 1csc culture in the ACA@AH microcapsule is further
confirmed using PC-3,MCF-7, andOVCAR-8 cells:∼7.0%, 5.5%,
and 4.2% of the cells under the 1csc culture are able to survive
and proliferate into colonies, respectively (Figure S8, Supporting
Information).
2.2. Gene and protein expression analyses
To gain a transcriptome-wide perspective of alterations in cel-
lular characteristics including stemness in response to the dif-
ferent methods for CSC isolation, we performed RNA sequenc-
ing (RNA-Seq) analyses on the cells in the colonies, spheroids,
and aggregates obtained from the 1csc, Mcells, and Ucells cul-
ture of MDA-MB-231 cells in CSC medium, together with cells
under 2D culture in non-CSC (or regular) medium (2Dcells, Fig-
ure 1e). Results obtained fromRNA-Seqwere further validated by
performing RT-PCR for six differentially expressed genes (Fig-
ure S9a, Supporting Information). First, we confirmed correla-
tion between the four sets of experiments by developing a Pear-
son correlation matrix (Figure S9b, Supporting Information). All
the triplicates are tightly and positively correlated (the diagonal of
the heat map, correlation value: 0.97–0.99) and the four culture
methods also exhibit high degree of positive correlation (>0.93).
This is not surprising as the cells studied in the four groups
are all derived from the same cell line. Next, to identify differ-
entially expressed genes, the volcano plots for the four culture
methods are assembled by plotting the negative log10 of the p
value on the y-axis, where highly significant changes appear high
on the plot (Figure S9c, Supporting Information). The expres-
sion of ∼37,000 genes in the cells of the 2Dcells, Ucells, Mcells,
and 1csc groups was analyzed. The results show that the 1csc
group has the highest number of differentially expressed genes
when compared with the other three groups (Figure S9b, Sup-
porting Information). A clustergram of the top 10,000 genes that
are differentially expressed among the four groups is shown in
Figure 2a. In addition, unsupervised hierarchical clustering leads
to their organization into distinct clusters. The 1csc group shows
significantly greater changes in its transcriptional profiles than
the other three groups. Specifically, 7007 (summation of num-
bers in the red circle), 8153 (summation of numbers in the green
circle), and 6713 (summation of numbers in the purple circle)
genes were differentially expressed in the 1csc group compared
to the 2Dcells, Ucells, and Mcells groups, respectively, as shown
by the Venn diagram in Figure 2b and Figure S9c (Supporting
Information). A total of 3362 genes were differentially expressed
in the 1csc group compared to all the other three groups.
Gene ontology (GO) enrichment analysis was also conducted
to determine the significantly altered genes in different bio-
logical processes. The top eight enriched GO terms are pre-
sented in Figure 2c. It shows that the biological processes re-
lated to cellular structure organization (chromatin organiza-
tion/transcription, cytoplasm organization, and cell transforma-
tion), cell proliferation (cell cycle regulation and autophagy), and
cellular stress-related signals (DNA repair and quantity of re-
active oxygen species, ROS) are significantly different in the
1csc group compared to all other groups (Figure 2c). The ex-
pression of genes that are relevant to stemness (positive and
negative) of CSCs, DNA repair, anti-apoptosis, and drug resis-
tance in the 1csc group compared to all other groups, is shown
in Figure 2d. Known functional markers of self-renewal (CD44
and BMI1) and malignancy (ALDH1A1, ALDH7A1) are signif-
icantly upregulated in the 1csc group (Figure 2d). Expression
of genes (CXCR4, CXCL3, and HGF) involved in secretion of
chemokines/cytokines in the tumor microenvironment is signif-
icantly upregulated in the 1csc group, as well (Figure 2d). In addi-
tion, genes for maintaining pluripotency (e.g., DPPA2, HDAC1,
HDAC2, and BMPER) are abundantly expressed in the 1csc
group. In contrast, genes (BMP2, BMP2K, BMP4, and CD24)
that promote differentiation and cellular proliferation are down-
regulated in the 1csc group (Figure 2d). It is worth noting that
some key genes (OCT4, SOX2,NANOG, andKLF4) important for
the maintenance of pluripotency are not upregulated in the 1csc
group. However, the expressions of these proteins are high in the
1csc group according to the confocal microscopy (Figure 2e) and
flow cytometry analyses with immunofluorescence staining (Fig-
ure 2f and Figure S10, Supporting Information). This is probably
because the translation of mRNAs into proteins is regulated by
many post-transcriptional processes in cells.[17] Indeed, further
analyses indicate that many repressors and activators associated
with these four stemness genes are downregulated and upregu-
lated, respectively, in the 1csc group (Figure S11, Supporting In-
formation). This may contribute to the increase in the activity of
the four proteins in the 1csc group. The stemness of the cells in
the 1csc group is also indicated by the increased expression of two
other commonly used protein markers of stemness, ALDHA1
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Figure 2. Characterization of stemness with gene and protein expressions. a) Differential gene expression heat map from RNA-sequencing (RNA-Seq)
of cells obtained from the 2Dcells, Ucells, Mcells, and 1csc cultures, showing the gene expression in the 1csc group is largely different from the other
three groups. b) Venn diagram for the differential gene expression heat maps of 2Dcells, Ucells, Mcells, and 1csc groups. c) Gene ontology (GO)
enrichment analysis of significantly altered genes in cells obtained from the 1csc versus 2Dcells, Ucells, and Mcells cultures. The whole-genome data
are representative of three independent experiments. d) Heat map of gene expression in cells of the 2Dcells, Ucells, Mcells, and 1csc groups regarding
stemness (including four downregulated differentiation marker genes), DNA repair, anti-apoptosis, drug resistance, and cell proliferation. e) Confocal
images of OCT4, KLF4, SOX2, NANOG, ALDHA1, and AP (alkaline phosphatase) protein expression in cells of the 2Dcells, Ucells, Mcells, and 1csc
groups. DAPI stains the cell nuclei. f) Representative flow cytometry peaks and quantitative analyses of the expression of OCT4, KLF4, SOX2, NANOG,
and ALDHA1 proteins in cells of the 2Dcells, Ucells, Mcells, and 1csc groups. The p values for the 1csc group versus the 2Dcells, Ucells, and Mcells
groups are <0.0001 for OCT4, <0.0001 for KLF4, 0.0009 for SOX2, <0.0001 for NANOG, and <0.0001 for ALDHA1. Error bars denote mean ± s.d., and
statistical significance was assessed by one-way ANOVA with post hoc Tukey test. ***p < 0.001.
and alkaline phosphatase (AP), compared with the other three
groups (Figure 2e and Figure S12, Supporting Information). The
capability of CSCs to survive in stressful conditions is correlated
to high expression of anti-apoptotic markers as well as protection
of genome integrity by prompt activation of DNA damage sensor
and repairmachinery.[18] Indeed,manyDNA repair-related genes
including the CCDH, ERCC, POLR2, and RPA families are up-
regulated in the 1csc group compared with the other three groups
(Figure 2d). In addition, the expressions of anti-apoptotic genes
(e.g., the BCL2L2 and CAP families) are significantly higher in
the 1csc group than the other three groups (Figure 2d). Cells in
the 1csc group also express elevated levels of drug-transporter
proteins (e.g., the ABCA1, ABCA8, and HSP90 families) to ex-
pel cytotoxic agents (Figure 2d), which may lead to high resis-
tance to chemotherapeutic drugs. CSC quiescence has also been
hypothesized to protect the cells against cytotoxic therapy.[19] In-
deed, many proliferation genes are downregulated in the 1csc
group (e.g.,ABL1, FOXO1, and FOXO3) compared with the other
three groups (Figure 2d).
2.3. Cross-tissue multilineage differentiation
Besides the expression of stemness genes and proteins,
a crucial characteristic of stem cells is their capability of
cross-tissue multilineage differentiation.[20] The MDA-MB-231
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Figure 3. Characterization of stemness with cross-tissue multilineage differentiation. a) A schematic illustration of the protocol for endothelial differen-
tiation and vascular tube formation. b) Immunofluorescence staining of human CD31 (hCD31) and ACTIN and DAPI staining of nuclei in cells of the
2Dcells, Ucells, Mcells, and 1csc groups cultured in endothelial growth medium (EGM) supplemented with 50 ng mL−1 of vascular endothelial growth
factor (VEGF), together with cells from the 1csc group cultured in CSC medium. DIC: Differential interference contrast. c) A schematic illustration of
the protocol for cardiac differentiation. d,e) Confocal images showing the expression level of two cardiac specific markers, cardiac troponin I (cTnI,
(d)) and 𝛼-ACTININ (e), in cells of the 2Dcells, Ucells, Mcells, and 1csc groups after cardiac differentiation. f) A schematic illustration of the protocol
for osteogenic differentiation. g) Typical pictures and microscopic images of the cells stained with Alizarin Red S to visualize calcium deposition after
osteogenic differentiation. h) Quantitative analysis of the absorbance of Alizarin Red S at 500 nm in the cells after osteogenic differentiation from the
2Dcells, Ucells, Mcells, and 1csc groups. The p value for the 1csc group versus 2Dcells, Ucells, and Mcells groups is <0.0001. Statistical significance
was assessed by one-way ANOVA with post hoc Tukey test. ***p < 0.001. i) A schematic illustration of the protocol for neural differentiation together
with confocal images showing the expression level of the neuron specific marker MUSASHI-1 (MUS) and the formation of the neurites in the differenti-
ated cells from the four groups. DAPI is for staining the cell nuclei and TUBULIN (TUB) is stained to show the cytoskeleton in cells. Error bars denote
mean ± s.d.
cells cultured with the aforementioned four methods were then
investigated for their capacity of endothelial, cardiac, osteogenic,
and neural differentiation. For endothelial differentiation, the
cell colonies/spheroids/aggregates were dissociated and the
2D cultured cells were detached into single cells for culture in
endothelial growth medium (EGM) supplemented with 50 ng
mL−1 vascular endothelial growth factor (VEGF) for 4–6 days.
Immunostainings of human CD31 and VE-CADHERIN indicate
that the cells derived from the 1csc group express significantly
higher levels of the two endothelial cell markers compared with
cells derived from the other three groups (Figure S13, Supporting
Information). The expression of endothelial cell markers is min-
imal when the cells obtained from the 1csc colonies are cultured
in the CSC medium, while the expression of OCT4 is stronger
in the 1csc colony cells cultured in the CSC medium than the
differentiation medium (Figure S13, Supporting Information).
Moreover, the cells differentiated from the 1csc group are able
to self-assemble into blood vessel-like structures after seeded on
Matrigel in differentiation medium for 12 h (Figure 3a,b and
Figure S14, Supporting Information). These data indicate func-
tional endothelial cells can be differentiated from the 1csc colony
cells. In stark contrast, no blood vessel formation is observable
when culturing the cells from the 2Dcells, Ucells, and Mcells
groups on Matrigel in endothelial differentiation medium or
the 1csc colony cells in CSC medium on Matrigel (Figure S14,
Supporting Information). It is worth noting that cells from the
2Dcells, Ucells, and Mcells groups could attach and proliferate
efficiently in culture medium or differentiation medium at least
for three passages (Figure S15, Supporting Information). In
contrast, the 1csc colony cells tend to form cell aggregates and
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most of them do not attach on the cell culture plate during pas-
sage 1. Surprisingly, starting from passage 2, the differentiated
cells in the 1csc group could not proliferate and further passaging
causes the cells to die and few cells could survive to passage 3 (Fig-
ure S15, Supporting Information). These data suggest the 1csc
colony cells lose their cancerous property after endothelial differ-
entiation and using VEGF to induce CSC endothelial differentia-
tionmight be a valuable strategy for cancer therapy. Thismay also
contribute to the observation that VEGF inhibitor-based cancer
therapy is at times associated with cancer drug resistance.[21]
We further conducted cardiac differentiation on the cells
obtained from the four different cultures using a two-step
differentiation assay from Thermo Fisher according to the
manufacturer’s instructions (Figure 3c and Figure S16, Support-
ing Information). Although we did not observe spontaneously
beating cardiomyocytes, the immunostaining data show that
high expression of multiple cardiac specific markers including
cardiac troponin I (cTnI) and 𝛼-ACTININ can be observed only
for the 1csc group (Figure 3d,e and Figure S17, Supporting In-
formation). Osteogenic differentiation was also conducted by uti-
lizing a kit from Thermo Fisher as per the manufacturer’s in-
structions (Figure 3f and Figure S18, Supporting Information)
and staining of calcium deposits with Alizarin Red S was used to
judge successful osteogenic differentiation.[22] As shown in Fig-
ure 3g,h, significantly more calcium deposits could be observed
in the 1csc group than the other three groups. Similarly, neural
marker (MUSASHI-1 or MUS staining) and neurite-like struc-
ture could be observed only for the 1csc group after neural dif-
ferentiation (Figure 3i and Figure S19, Supporting Information).
All the aforementioned differentiation studies show that only
the 1csc colony cells possess the capability of cross-tissue mul-
tilineage differentiation, indicating they are truly CSCs. Cells ob-
tained from the conventional Mcells, Ucells, and 2Dcells cultures
may not be CSCs because they lack the key feature of cross-tissue
multilineage differentiation for stem cells.
2.4. In vivo tumorigenesis
After confirming the stemness of the 1csc colony cells in vitro, we
investigated the in vivo tumorigenic capability of the colony cells
as compared to cells from the 2Dcells, Ucells, andMcells groups.
As schematically illustrated in Figure 4a, three generations (G1–
G3) of tumors were produced: the first generation (G1) tumors
were generated using cells obtained from the MDA-MB-231 cells
under 2Dcells (2D), Ucells (U), Mcells (M), and 1csc (1) cultures
by injecting them into the mammary fat pads of immunodefi-
cient mice; cells isolated from the G1 tumors (2D, U,M, and 1) of
the four groups were then under the 1csc culture to obtain colony
cells for injecting into the fat pads of immunodeficient mice to
generate the second generation (G2) tumors (2D-1, U-1, M-1, and
1-1); and cells were again isolated from theG2 tumors and further
cultured using the 1cscmethod to obtain colony cells for injecting
into the fat pads of immunodeficient mice to generate the third
generation (G3) tumors (2D-1-1, U-1-1, M-1-1, and 1-1-1). A total
of 500 cells were injected into each mouse and the tumor growth
wasmonitored for 55 days. Due to the small number of cells used
for injection into each mouse, G1 tumor formation was observed
in only 4 out of the 8 mice (TF = 4/8) for the 2Dcells and Mcells
groups (Figure 4b,c and Figure S20a, Supporting Information).
Although the G1 tumor formation does occur in 8 out of 8 mice
(TF = 8/8) for both the Ucells and 1csc groups, the G1 tumors in
the 1csc group grow much faster and are much bigger than that
in all the other three groups. Interestingly, we do not observe any
significant difference in tumor growth among the Ucells, Mcells,
and 2Dcells groups, indicating the inability of the conventional
methods for isolating CSCs (at least for the MDA-MB-231 cells
line). To check the difference in transcriptome profile of the 1csc
colony cells before (in vitro) versus after (in vivo) injection into
mice, we performed RNA-Seq on cells isolated from the G1 tu-
mors in the 1csc group. As shown in Figure S20b (Supporting
Information), all the triplicates correlate very well. Interestingly,
many genes were differentially expressed between the in vitro
1csc colony cells and the cells of the in vivo tumors grown from
the in vitro 1csc colony cells, as shown in the clustergram of the
top 11,530 genes (Figure 4d and Figure S20c, Supporting Infor-
mation). Specifically, 7883 genes are significantly downregulated
whereas 3647 genes are significantly upregulated after injecting
the in vitro 1csc colony cells into mice to grow in vivo tumors
(Figure 4e). We further found that almost half of the upregulated
genes in in vivo tumors were related to cellular growth and prolif-
eration, suggesting that cellular proliferation of the 1csc colony
cells is significantly altered after in vivo injection probably due
to their spontaneous differentiation into tumor cells in vivo (Fig-
ure 4f). Additionally, the expression of most of the genes related
to stemness, DNA repair, anti-apoptosis, and drug resistance is
significantly decreased in in vivo tumors compared to the in vitro
1csc colony cells and is similar to that in the 2D cultured cells
(2Dcells, Figure 4g).
In order to examine if the 1csc culture approach can be used
to isolate CSCs from in vivo tumors, cells from the G1 in vivo
tumors of the four different groups (2D, U, M, and 1) were iso-
lated and cultured using the 1csc approach with one single cell
in each ACA@AH microcapsule in CSC medium. Interestingly,
only ∼3–5% of the tumor cells are able to form colonies for all
the four groups (Figure S21a, Supporting Information). Further-
more, all the 1csc colony cells obtained from the four groups are
able to form the G2 (2D-1, U-1, M-1, and 1-1) in vivo tumors in
the mouse mammary fat pads efficiently (TF = 8/8, Figure 4h,i
and Figure S22a,b, Supporting Information). Similarly, the G3 in
vivo tumor formation was performed by culturing cells from the
G2 (2D-1, U-1, M-1, and 1-1) tumors using the 1csc culture to
obtain colony cells for injecting into the mouse fat pads. As with
cells from theG1 tumors, only∼3–5% of the cells from theG2 tu-
mors could form a colony in each ACA@AH microcapsule (Fig-
ure S21b, Supporting Information). Growth of the G3 (2D-1-1, U-
1-1,M-1-1, and 1-1-1) tumors (Figure 4j,k and Figure S22c,d, Sup-
porting Information) is similar to that of the aforementioned G2
and 1csc G1 tumors. Taken together, a total of three generations
of in vivo tumorigenesis studies indicate that the colony cells
from the 1csc culture are significantly much more tumorigenic
than cells derived from the 2Dcells, Mcells, and Ucells cultures.
To further confirm this, cells were isolated from the G1 (1) and
G2 (1-1) tumors grown from the 1csc colony cells and cultured us-
ing the three conventional culturemethods (2Dcells or 2D,Ucells
or U, and Mcells or M). The resultant cells were injected into
the mouse fat pad for generating the second-generation (1-2D,
1-U, 1-M, Figure 4l,m) and third-generation (1-1-2D, 1-1-U, and
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Figure 4. Characterization of stemness with multi-generation tumorigenesis assay in vivo. a) A schematic illustration of the three-generation (G1–G3)
in vivo tumorigenesis assay. The G1 tumors were grown from cells obtained by 2Dcells, Ucells, Mcells, and 1csc cultures of the MDA-MB-231 cells; the
G2 tumors were grown from cells obtained by 1csc culture of the four types of G1 tumor cells; and the G3 tumors were grown from cells obtained by
1csc culture of the G2 tumor cells in the four groups. b,c) Individual growth curves of the G1 tumors (2D, U, M, and 1) in 55 days (b) and weight of the
G1 tumors on day 55 (c) for the four groups. The p value for the 1csc (1) group versus the 2Dcells (2D), Ucells (U), and Mcells (M) groups is <0.0001.
Statistical significance was assessed by one-way ANOVA with post hoc Tukey test. ***p < 0.001. d) Differential gene expression heat map from RNA-Seq
analysis of cells in the 1csc group before injection into mice (in vitro) and cells in tumor (in vivo) grown from the 1csc in vitro cells. e) The distribution of
down- and upregulated genes in the in vivo cells as compared to the in vitro cells in the 1csc group. f) Pathway analysis of significantly altered genes in
the 1csc in vivo cells as compared to the 1csc in vitro cells. The whole-genome data are representative of three independent experiments. g) Heat map
of gene expression in the 1csc in vitro and in vivo cells together with in vitro 2D cultured cells (2Dcells) regarding stemness (positive and negative),
DNA repair, anti-apoptosis, drug resistance, and cell proliferation. The gene expression of 1csc in vivo cells is closer to that of cells in the 2Dcells group
than 1csc in vitro cells. h,i) Individual growth curves of G2 tumors (2D-1, U-1, M-1, and 1-1) in 55 days (h) and weight of the G2 tumors on day 55 (i) for
the four groups. j,k) Individual growth curves of G3 tumors (2D-1-1, U-1-1, M-1-1, and 1-1-1) in 55 days (j) and weight of the G3 tumors on day 55 (k)
for the four groups. l) A schematic illustration of the second-generation tumors grown from cells obtained by 2Dcells, Ucells, and Mcells cultures of the
1csc G1 tumor cells (left), together with the individual growth curves of the tumors (1-2D, 1-U, and 1-M) (right). m) Weight of the 1-2D, 1-U, and 1-M
tumors on day 55. n) A schematic illustration of the third-generation tumors grown from cells obtained by 2Dcells, Ucells, and Mcells cultures of the
1csc G2 tumor cells (left), together with the individual growth curves of the tumors (1-1-2D, 1-1-U, and 1-1-M) (right). o) Weight of the 1-1-2D, 1-1-U,
and 1-1-M tumors on day 55. TF: tumor formation in mice on day 55.
1-1-M, Figure 4n,o) tumors. As shown in Figure 4l,m, the growth
of the second-generation 1-2D, 1-U, and 1-M tumors is much
slower than the G2 2D-1, U-1, M-1, and 1-1 tumors and the dif-
ference in tumor weight is significant (Figure S22a,b, Supporting
Information). Similarly, the third-generation 1-1-2D, 1-1-U, and
1-1-M tumors growmuch slower than the G3 2D-1-1, U-1-1, M-1-
1, and 1-1-1 tumors, and the difference in tumor weight is signif-
icant (Figure 4n,o and Figure S22c,d, Supporting Information).
To find out why the 1csc colony cells are highly tumorigenic,
histology of the tumor tissues was analyzed through hema-
toxylin and eosin (H&E) staining. Interestingly, the percentage
of necrotic area in the tumors grown from cells obtained with
the 2Dcells, Ucells, and Mcells cultures is significantly larger
than that in tumors grown from the 1csc colony cells for all three
generations (G1–G3) (Figures S23–S25, Supporting Informa-
tion). This is possibly because the 1csc colony cells can better
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Figure 5. Characterization of stemness with metastasis assay in vivo. a) A schematic illustration of the protocol of the metastasis assay. Cells from the
2Dcells, Ucells, Mcells, and 1csc cultures are used for injection into mice via their tail vein and the corresponding metastasis study groups are called
2Dmeta, Umeta, Mmeta, and 1meta, respectively. b,c) Representative photographs of the Bouin solution-fixed lungs (b) and the weight of the lungs
(before fixation, (c)) from the 2Dmeta, Umeta, Mmeta, and 1meta groups. The p value for the 1meta group versus the 2Dmeta, Umeta, and Mmeta
groups is 0.0005. Statistical significance was assessed by one-way ANOVA with post hoc Tukey test. ***p < 0.001. d) Typical images of hematoxylin and
eosin (H&E) stained lung tissue from the 2Dmeta, Umeta, Mmeta, and 1meta groups, showing metastasis (arrow) in the lungs of the 1meta group. e)
Quantitative analysis of metastatic tumors observed in the H&E slide. The p values for the 1meta group versus the 2Dmeta, Umeta, and Mmeta groups
is <0.0001 and statistical significance was assessed by one-way ANOVA with post hoc Tukey test. ***p < 0.001. f) Representative fluorescence images of
lung tissues from the 2Dmeta, Umeta, Mmeta, and 1meta groups after immunostaining for human CD44 and Ki-67. The human CD44 and Ki-67 could
be seen only in the 1meta group. Error bars denote mean ± s.d.
regenerate the tumormicroenvironment than cells obtained with
the other three culturemethods. For example,more blood vessels
can be observed in the tumors grown from the 1csc colony cells
than cells obtained with the other three culture methods (Fig-
ures S23–S25, Supporting Information), whichmay be attributed
to the endothelial differentiation capability of the 1csc colony cells
(Figure 3a,b). This is confirmed by immunofluorescence staining
of human endothelial cell markers hCD31 and hVE-CADHERIN:
much higher expression of hCD31 and hVE-CADHERIN can
be observed in the 2D-1-1, U-1-1, M-1-1, and 1-1-1 tumors than
1-1-2D, 1-1-U, and 1-1-M tumors, although the expression of
mouse endothelial cells marker (mCD31) is evident in all the
tumors (Figure S26, Supporting Information). Increased blood
vessels facilitate the transport of nutrients and oxygen inside
tumors, which may contribute to the reduced necrosis observed
in the tumors grown from the 1csc colony cells. It is worth noting
that other mechanisms may contribute to the fast proliferation
of tumors grown from the 1csc colony cells, such as the high ex-
pression of proliferating cell nuclear antigen (PCNA, Figure S27,
Supporting Information) that promotes cell proliferation.
2.5. In vivo metastasis
Besides high tumorigenesis, CSCs have been posited to cause
metastases. To investigate this, attached cells and cell aggre-
gates/spheroids/colonies from the 2Dcells, Ucells, Mcells, or
1csc cultures were dissociated into single cells for injection into
C57BL/6 mice with intact immune system via their tail veins (2
× 106 cells per mouse, Figure 5a). The mice were sacrificed after
2 months and the lungs from the four groups (2Dmeta, Umeta,
Mmeta, or 1meta) were collected for further analyses. First, all
the lungs in the 1meta group appear larger than that in the other
three groups (Figure 5b), and all the lungs in the 1meta group are
significantly heavier than that in all the other three groups (Fig-
ure 5c). This is possibly due to the formation of cancermetastases
in this group. Indeed, further histology analyses with H&E stain-
ing show that metastases of a few hundred microns in size with
densely packed cells formed in all the lungs of the 1meta group
(Figure 5d,e). The metastatic tumors in the lungs of the 1meta
group are further confirmed by immunofluorescence staining
with human CD44 and Ki-67 (Figure 5f). In stark contrast, no
metastasis was observed in any of the lungs of the 2Dmet and
Umeta groups and only onemetastasis was observed in one of the
lungs of the Mmeta group. This is probably because the cancer
cells injected intomice for these groups are not stem cells and can
be easily killed by the immune system of the mice. For the 1csc
group, the colony cells are likely stem cells andmay evade the im-
mune system of the mice. The capability of human stem cells in
evading the immune system to survive in murine species (mice
and rats) has also been reported in the literature.[23] It is worth
noting that metastatic tumors were also observed in the liver and
kidney of mice (2/8) in the 1meta group (Figure S28, Support-
ing Information). The seeding and growth of breast metastatic
tumors at sites distant from the primary tumor is a complex
and multistep process, and the epithelial-mesenchymal transi-
tion (EMT) has been considered a major mechanism for breast
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Figure 6. Implications for developing CSC-targeted therapeutic strategies. a,b) Viability of the cells obtained by 2Dcells, Ucells, Mcells, and 1csc cultures
of MDA-MB-231 cells after treating them with doxorubicin hydrochloride (DOX, (a)) and camptothecin-11 (CPT-11, (b)). For DOX, the p value for the
1csc group versus the 2Dcells, Ucells, and Mcells groups is <0.0001 for both 10 and 5 µg mL−1. For CPT-11, the p value for the 1csc group versus the
2Dcells, Ucells, and Mcells groups is <0.0001 for 50 µg mL−1 and it is 0.0034 for 10 µg mL−1. Error bars denote mean ± s.d., and statistical significance
was assessed by one-way ANOVA with post hoc Tukey test. **p < 0.01, and ***p < 0.001. c) Gene set enrichment analysis (GSEA) of the signaling
pathways enriched in 1csc colony cells compared with cells from the 2Dcells, Ucells, and Mcells cultures. d) Overall survival via Kaplan–Meier Estimate
of patients with enriched core genes in oxidative phosphorylation, mitochondrial dysfunction, EIF2 signaling, MYC targets, DNA repair, and fatty acid
metabolism pathways (red line). The blue line shows the survival of patients without enrichment in the respective pathways. Statistical significance was
assessed by Kaplan–Meier survival analysis.
cancer metastasis.[24] Increased VIMENTIN expression is fre-
quently used as an EMT marker in cancer and there is a positive
correlation of VIMENTIN expression with augmented invasive-
ness andmetastasis.[25] Indeed, as shown in Figure S29 (Support-
ing Information), higher expression of VIMENTIN is observed
in the 1csc colony cells than cells from the other three groups.
Moreover, decreased expression of E-CADHERIN and increased
expression of 𝛽-CATENIN are observed in the 1csc colony cells
compared with cells in the other three groups (Figure S29, Sup-
porting Information). Previous studies suggest that the suppres-
sion of E-CADHERIN and increased expression of 𝛽-CATENIN
lead tomesenchymal phenotype, increased cell migration and in-
vasion, and enhancedmetastasis.[26] Similarly, these data suggest
that the 1csc colony cells possess stronger capacity of invasion
and migration than cells in the other three groups.
2.6. Drug resistance and clinical significance
Having demonstrated the stemness of the 1csc colony cells
through the serial passaging assay in vitro, gene and protein ex-
pression analyses of in vitro and in vivo cells, and studies onmul-
tilineage differentiation, three generations of in vivo tumorige-
nesis, and metastatic capacity, we next treated these cells with
two chemotherapeutic drugs, doxorubicin hydrochloride (DOX)
and camptothecin-11 (CPT-11). It is found that the 1csc colony
cells are significantly more resistant to both drugs than cells ob-
tained with the other three culture methods (Figure 6a,b). This
is not surprising, as the upregulation of many CSC-related genes
(e.g., DNA repair, anti-apoptosis, and drug resistance) and down-
regulation of proliferation-related genes (Figure 2d) should ren-
der the 1csc colony cells highly resistant to chemotherapeutic
drugs. In order to find potential therapeutic targets of CSCs to
overcome their drug resistance, differentially regulated canon-
ical pathways as well as genes were analyzed. The results are
shown in Figure S30 (Supporting Information). In conjunction to
alterations in stemness related pathways (Figure S30a, Support-
ing Information), pathways related to energy metabolism (e.g.,
oxidative phosphorylation and mitochondrial dysfunction, Fig-
ure S30b, Supporting Information) are significantly altered in the
1csc group compared with the other three groups. Additionally,
similar pathways (oxidative phosphorylation and mitochondrial
dysfunction) are altered between the in vitro 1csc colony cells and
in vivo tumors grown from them (Figure S31, Supporting Infor-
mation), suggesting these pathways may play an important role
in supporting/maintaining the stemness of the 1csc colony cells.
Differences in energy metabolism are also revealed by utilizing
gene set enrichment analysis (GSEA) of the top 23 enriched path-
ways with hallmarks (Figure S32, Supporting Information), and
the top 10 are given in Figure 6c. These enriched pathways in the
1csc colony cells are involved in improved stemness, decreased
cell growth, anti-apoptosis, increased drug resistance, enhanced
DNA repair, and reduced metabolism, which are considered im-
portant properties of CSCs (Figure 6c and Figure S32, Supporting
Information). Most of the signaling pathways are also different
between the in vitro 1csc colony cells and the in vivo 1csc tumor
cells, and the top 39 are given in Figure S33 (Supporting Infor-
mation).
Lastly, we examined the clinical significance of targeting the
CSCs isolated with the 1csc culture by investigating the survival
of breast cancer patients with alterations in the top enriched
gene sets found from our GSEA analyses of the 1csc colony
cells as compared to cells in the 2Dcells, Ucells, and Mcells
groups. These include oxidative phosphorylation, mitochondrial
dysfunction, EIF2 targets, MYC targets, DNA repair, and fatty
acid metabolisms (Figure 6c and Figures S30–32, Supporting In-
formation). As shown by the Kaplan Meier estimates of survival
(Figure 6d), alterations of these gene sets decrease the prognostic
outcomes in breast cancer patients, suggesting that they can be
potential therapeutic targets for eliminating CSCs to improve
breast patient survival. Perhaps, the combination of inhibitors
of these pathways and/or their further combination with factors
for guided differentiation (e.g., VEGF for endothelial differ-
entiation so that the cells lose cancerous property and do not
proliferate, Figure S15, Supporting Information) may be used
to target CSCs and achieve improved outcomes of breast cancer
therapy.
Adv. Sci. 2020, 7, 2000259 2000259 (10 of 12) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advancedscience.com
3. Conclusions
In conclusion, inspired by the prehatching embryos which start
proliferation from one cell to form a colony, we developed a
one-single-cell-microencapsulation (1csc) method to isolate and
culture CSCs without needing any surface marker. Hyaluronic
acid was found to be crucial for the CSCs to survive and form
colonies under the 1csc culture and the CSCs take up ∼3–5%
the whole cancer cell population. Genome profiling indicates
that the stemness, DNA repair, anti-apoptosis, and drug resis-
tance of the 1csc colony cells are enhanced while their tendency
of proliferation is decreased compared with 2D cultured cells
and cells obtained with the conventional approaches for isolat-
ing CSCs. Furthermore, the CSCs obtained with the 1csc culture
are capable of cross-tissuemultilineage (e.g., endothelial, cardiac,
osteogenic, and neural) differentiation. Moreover, three genera-
tions of in vivo tumorigenesis studies together with investiga-
tions onmetastasis indicate that the CSCs are highly tumorigenic
andmetastatic. The CSCs are also shown to be highly resistant to
chemotherapeutic drugs DOX and CPT-11. Our one-single-cell-
microencapsulation approach for CSC isolation and culture may
be valuable for understanding cancer biology and etiology and
for facilitating the development of CSC-targeted effective thera-
pies to fight against cancer.
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